• 목록
• 답변

Arbormed, an Innovative Drug Development, succeeded in attracting funding 6 billion won in investment before listing

Strengths such as listing target in 2023, technology development-licensing... SBI and Hana Financial Investment company participated in Series A

Arbormed, which runs a business model for technology transfer after bringing in new drug technology in the early research stage and progressing research before commercialization,
 succeeded in attracting initial investment from domestic investors.
According to related industries on the 5th, Arbormed recently succeeded in attracting 6 billion won in Series A investment from SBI, Hana Financial Investment, Broadhill,
Aion Asset Management, and Comes Investment.

Park Kyo-jin, co-chairman of Arbormed, met with Money Today news and said, "The funds raised by Series A will be used to complete the preclinical phase of new drug substances
and prepare for the distribution of Korean medicines in the U.S. market."
He also said, "We will complete a global technology transfer deal by the 2023 KOSDAQ market listing target period after raising the research on new drug substances currently secured
by attracting Series B investment in the second half of next year (2021)."

Arbormed was established in December 2017 and is a start-up company that has not yet been three years. Nevertheless, the company's success in attracting initial investment
 was attributed to the capabilities of its major personnel. After graduating from the University of Michigan's Graduate School of Business Administration (MBA),
CEO Park has been working as a licensing expert for a long time. In other words, he has long worked to secure technology transactions by connecting one company
with potential new drug substances and another company in demand to develop and commercialize the substance.
 CEO Park said that Lego Chem Bio, a Korean KOSDAQ-listed company, was Takeda of Japan last year and has also been involved in the process of signing technology
 transfer transactions for pharmaceuticals.

Lim Won-bin, who is co-chairman with CEO Park, has been working for Dong-A Pharmaceutical for 30 years from 1990 to 2020, and has been working on new drug research.
CEO Lim will be in charge of progressing research on new drug substances that CEO Park has introduced until the stage before commercialization, and CEO Park will transfer
the technology to global pharmaceutical companies overseas.
In addition, Vice President Han Won-sun, who has worked at Yale University's Technology Transfer Center in the U.S., and Eun So-young, director of research and development,
who worked at the Green Cross Mokam Research Institute.

Arbormed plans to not only import new drug technology and export technology again but also run a Korean drug distribution business in the U.S. market through its U.S. branch.
It is already securing three pipelines: Wilson's disease (a rare genetic disease that causes problems with copper metabolism) treatment, rheumatism, psoriasis treatment,
and anesthetics introduced by its U.S. partner. It is also in the process of distributing drugs from domestic pharmaceutical companies to the U.S. market, such as
Korea United Pharmaceutical's anticancer injection, iCURE's pain relief patch, and Pepmix's injection.